Evidence map›Paper›PMID 37369376›Full record

GuidelineInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2023

European Society of Gynaecological Oncology Guidelines for the Management of Patients with Vulvar Cancer - Update 2023.

Maaike H M Oonk, François Planchamp, Peter Baldwin, Sven Mahner, Mansoor Raza Mirza, Daniela Fischerová, Carien L Creutzberg, Eugénie Guillot, Giorgia Garganese, Sigurd Lax and 10 more

Registry-linked trialOpen access · hybridAbstract readPractice Guideline
In one paragraph

Guideline in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06911801 (In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer), which is not on this map. Cited by 100 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed, 6 pooled it
55.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06911801 not yet recruitingnot on this mapstarted 2025, after this paper: background citation

In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer

TypeobservationalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2025 to 2026Enrolled90ConditionsVulvar Squamous Cell Carcinoma
3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 6 syntheses or guidelines pooled it, 187 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Let's talk about sex: consensus guidelines of the GINECOR working group of the Spanish Society of Radiation Oncology: clinical recommendations after pelvic radiotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2025
    Guideline
  5. Pooled it
  6. Pooled it
  7. [Vulvar intraepithelial neoplasia and vulvar cancer].Dermatologie (Heidelberg, Germany) · 2026
    Review
  8. Article
  9. Review
  10. Article
  11. Vulvar Squamous Cell Carcinoma: Scientific Progress and Impacts to Pathology Practice.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2026
    Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Spatio-temporal inequalities in vulvar cancer mortality in Spain, 1999-2023: a nationwide Bayesian analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  17. Article
  18. Article
  19. Article
  20. Review

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 12 countries.

Maaike H M OonkUniversity Medical Center Groningen, Groningen, The Netherlands m.h.m.oonk@umcg.nl.
François PlanchampInstitut Bergonie, Bordeaux, France.ORCID 0000-0002-8709-0410
Peter BaldwinAddenbrooke's Hospital, Cambridge, UK.
Sven MahnerUniversity Hospital, Ludwig Maximilians University Munich, Munich, Germany.
Mansoor Raza MirzaRigshospitalet; Copenhagen University Hospital, Copenhagen, Denmark.
Daniela FischerováCharles University First Faculty of Medicine, Prague, Czech Republic.ORCID 0000-0002-7224-3218
Carien L CreutzbergLeiden University Medical Center, Leiden, The Netherlands.
Eugénie GuillotInstitut Curie, Paris, France.
Giorgia GarganeseCatholic University of the Sacred Heart, Rome, Italy.
Sigurd LaxHospital Graz II, Graz, Austria.
Andres RedondoLa Paz University Hospital, Madrid, Spain.
Alina SturdzaUniversity Hospital Vienna, Vienna, Austria.
Alexandra TaylorRoyal Marsden NHS Foundation Trust, London, UK.ORCID 0000-0001-8100-5388
Elena UlrikhAlmazov National Medical Research Center, Saint Petersburg, Russian Federation.ORCID 0000-0002-2701-8812
Vincent VandecaveyeKU Leuven University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-0800-3279
Ate van der ZeeUniversity Medical Center Groningen, Groningen, The Netherlands.
Linn WölberUniversity Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Diana ZachKarolinska University Hospital, Stockholm, Sweden.
Gian Franco ZannoniCatholic University of the Sacred Heart, Rome, Italy.ORCID 0000-0002-4473-7560
Ignacio ZapardielLa Paz University Hospital, Madrid, Spain.ORCID 0000-0002-9175-7767
Hospital Universitario La Paz · ESUniversità Cattolica del Sacro Cuore · ITUniversity Medical Center Groningen · NLAddenbrooke's Hospital · GBCharles University · CZCopenhagen University Hospital · DKFederal Almazov North-West Medical Research Centre · RUInstitut Bergonié · FRInstitut Curie · FRJohannes Kepler University of Linz · ATKarolinska University Hospital · SEKU Leuven · BELeiden University Medical Center · NLLudwig-Maximilians-Universität München · DERoyal Marsden NHS Foundation Trust · GBUniversität Hamburg · DEVienna General Hospital · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs part of its mission to improve the quality of care for women with gynecological cancers across Europe, the European Society of Gynaecological Oncology (ESGO) first published in 2017 evidence-based guidelines for the management of patients with vulvar cancer.

objectiveTo update the ESGO guidelines based on the new evidence addressing the management of vulvar cancer and to cover new topics in order to provide comprehensive guidelines on all relevant issues of diagnosis and treatment of vulvar cancer.

methodsThe ESGO Council nominated an international development group comprised of practicing clinicians who provide care to vulvar cancer patients and have demonstrated leadership through their expertize in clinical care and research, national and international engagement and profile as well as dedication to the topics addressed to serve on the expert panel (18 experts across Europe). To ensure that the statements were evidence-based, new data identified from a systematic search were reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the international development group. Prior to publication, the guidelines were reviewed by 206 international practitioners in cancer care delivery and patient representatives.

resultsThe updated guidelines cover comprehensively diagnosis and referral, staging, pathology, pre-operative investigations, surgical management (local treatment, groin treatment, sentinel lymph node procedure, reconstructive surgery), (chemo)radiotherapy, systemic treatment, treatment of recurrent disease (vulvar, inguinal, pelvic, and distant recurrences), and follow-up. Management algorithms are also defined.

Indexed as

GynecologyPlastic Surgery ProceduresVulvar NeoplasmsEuropeFemaleHumansVulvar and Vaginal Cancer

Identifiers

PMID37369376
PMCPMC10359596
OpenAlexW4382246212

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.